Previous close | 10.38 |
Open | 10.32 |
Bid | 10.22 x N/A |
Ask | 10.34 x N/A |
Day's range | 10.20 - 10.32 |
52-week range | 4.20 - 12.00 |
Volume | |
Avg. volume | 7,256 |
Market cap | 191.908M |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MILAN & MORRISTOWN, N.J., June 05, 2024--Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City. New hope emerges for treatment-resistant schizophrenia.
MILAN, May 13, 2024--Newron reports new data from pivotal study 008A for chronic schizophrenia patients revealing clinically significant efficacy benefits over time.
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients